We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Treatment of Hyperkalemia From “Hyper K+” Strikeout to Home Run?

Wolfgang C. Winkelmayer, MD, ScD1,2
[+] Author Affiliations
1Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas
2Associate Editor, JAMA
JAMA. 2015;314(2):129-130. doi:10.1001/jama.2015.7521.
Text Size: A A A
Published online


Potassium is a key cation with tightly regulated extracellular concentration. Hyperkalemia, commonly considered present if the potassium concentration exceeds 5.0 mEq/L, appears to be a relatively rare event. Although representative data on hyperkalemia in the overall population are lacking, a study of US veterans indicated a hyperkalemia (defined as potassium concentration ≥5.5 mEq/L) event rate of approximately 4 per 100 person-years, with the majority of events occurring during hospitalizations.1 Individuals in this study were required to have at least 1 hospitalization and 1 outpatient creatinine measurement; thus, it is likely that the population was at higher risk for hyperkalemia. In contrast to the low rate of hyperkalemia in the general population, individuals with certain comorbid conditions, such as chronic kidney disease (CKD), diabetes, or congestive heart failure have been shown to be highly prone to developing hyperkalemia, especially if receiving treatment with inhibitors of the renin-angiotensin-aldosterone system (RAAS), which are often recommended in such patients. For example, in a randomized placebo-controlled trial of losartan in patients with diabetic nephropathy, the cumulative incidence of hyperkalemia (potassium concentration >5.0 mEq/L) was 38.4% in the losartan group.2

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Patiromer: The First Potassium Binder Approved in Over 50 Years. Cardiol Rev Published online Aug 18, 2016;
New drugs to prevent and treat hyperkalemia. Curr Opin Nephrol Hypertens Published online Aug 31, 2016;